AZILECT(R) Shown To Be A Selective MAO-B Inhibitor - Teva To Work With FDA To Modify The Azilect(R) Label
Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) today announced results of a study in which Azilect® (rasagiline tablets) demonstrated selective MAO - B inhibition at the approved dose of 1mg. Non selective MAO inhibitors may have some contra indications with certain foods and drugs. These limitations are not associated with selective MAO inhibitors and therefore they […]